Overview
AZD5438 in Patients With Advanced Solid Malignancies
Status:
Completed
Completed
Trial end date:
2005-12-01
2005-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZeneca
Criteria
Inclusion Criteria:- Advanced solid malignancy
- Cancer refractory to standard treatments or for which no standard therapy exits
Exclusion Criteria:
- Radiotherapy within 3 weeks of the start of treatment
- Investigational product within the last 3 weeks
- Systemic cytotoxic anti-cancer therapy within the last 3 weeks
- Any significant clinical disorder that makes it undesirable for the patient to
participate